



## **ISPOR Russia St. Petersburg Chapter**

Annual Report 2014

To:

Board of Directors

International Society for Pharmacoeconomics and

Outcomes Research

505 Lawrence Square Boulevard South

Lawrenceville, NJ 08648, USA

### **PREPARED BY**

Professor Alexey Kolbin, MD, PhD, Doctor of Science  
Head of the Department of Clinical Pharmacology and Evidence-based Medicine  
First Pavlov State Medical University of St. Peterburg  
Professor of Department of Pharmacology, Faculty of Medicine St. Petersburg State University  
197022, Russia, St. Petersburg, Lva Tolstogo 6-8  
Tel: 89217590449  
Email: alex.kolbin@mail.ru

### **Background:**

ISPOR Russia St. Petersburg Chapter was approved in November 2012.

*President of ISPOR Russia St. Petersburg Chapter*

**Alexey Kolbin, MD, PhD**

Doctor of Science Head of the Department of Clinical Pharmacology and Evidence-based Medicine First Pavlov State Medical University of St. Petersburg Professor of Department of Pharmacology, Faculty of Medicine St. Petersburg State University Head of the Regional Centre for the Monitoring of the Safety of Medicines (Pharmacovigilance) in the North-Western Federal District of Russia and the city of St Petersburg St P Russia, Saint Petersburg

*Vice President*

**Edwin Zvartau, MD, PhD**

Doctor of Science, Professor, Head of the Department of Pharmacology

*Executive Director*

**Dmitry Belousov, DrPH, MD**

CEO of Center for Pharmacoeconomics Research

*External Relations Director*

**Zakhar Golant, PhD**

Head of the Board at NCP "Medical-pharmaceutical projects "XXI century" (cluster organization)

*Secretary*

**Alexey Kurilev, MD**

Medical expert of Laboratory of Clinical Pharmacology

*Members of the ISPOR Russia St. Petersburg Chapter Executive Committee*

**Alexandra Burbello, MD, PhD**, Doctor of Science, Nord-West State Medical University, Professor, Clinical pharmacologist; **Alla Rudakova, PharmD, PhD**, Doctor of Science, SPbCPhA, Professor; **Andrey Pavlysh, MD, PhD**, Pavlov State Medical University of Saint Petersburg; **Boris Andreev, MD**, Doctor of Science, Professor, St. Petersburg State University, Head of the Department of Pharmacology; **Georgy Manikhas, MD, PhD**, Doctor of Science, City Oncological Clinic, Head; **Yulia Balykina, MS**, St Petersburg State University, Assistant; **Maksim Proskurin, MS**, St Petersburg State University, Assistant; **Julia Gomon, DrPH, MD**, St. George the Martyr City Hospital, Clinical Pharmacologist; **Nikolai Klimko, MD, PhD**, Doctor of Science, North-Western State Medical University, Head of the department; **Sergey Zyryanov, MD, PhD**, Doctor of Science, Russian State Medical University, Professor, Head of the Laboratory of Clinical Pharmacology; **Oleg Karpov, MD, PhD**, Doctor of Science, Professor, Sanofi, Head of Health Economics and Pricing Policy, Market Access Department; **Natalia Zakharova, MD, PhD**, Doctor of Sciences, Professor, North-Western State Medical University; **Stanislav Malyshev**, St. Petersburg State University, student.

For more information of Chapter, please visit at [http://www.ispor.org/regional\\_chapters/Russia-StPetersburg/index.asp](http://www.ispor.org/regional_chapters/Russia-StPetersburg/index.asp) and <http://www.labclinpharm.ru>.

**Activities of the Chapter can be summarized as follows:**

**I. The following articles have been published in Russian and International journals about pharmaco-economic and health technology assessment researches:**

№	Title	Journal	Author
1.	Pharmaco-economic Analysis of Telmisartan in Combination with Amlodipine (Tvinsta®) for Outpatient Treatment of Patients with 1 <sup>st</sup> and 2 <sup>nd</sup> degree hypertension with Ineffectiveness of Previous Monotherapy with Amlodipine.	Clinical Pharmacology and Therapy. 2014, 23 (1). – P.1-6.	A.S. Kolbin, A.A. Kurylev, M.A. Proskurin, Y.E. Balykina
2.	International Pharmaco-economic Studies on HIV-Infection	Economic and Clinical Issues of HIV Infection. Ed. by N.A.Belyakova, N.G.Zaharova, N.V.Sizova. Medical theme archive. St. Petersburg: Baltic Medical Education Center, 2014. Issue 6. – P. 5-20.	Kolbin A.S., Kurylev A.A., Musatov B.V., Yakovlev A.A.
3.	Comparative Analysis of Health Technology Assessment	Armenian Medical Review Journal, 2014, - P.34.	Kolbin A.S., Pavlysh A.V., Kurylev A.A., Belousov D.Yu.
4.	Pharmaco-economic Analysis of Telmisartan / Amlodipine (Tvinsta®) in Patients with 1 <sup>st</sup> and 2 <sup>nd</sup> Degree Hypertension with Ineffectiveness of Monotherapy with Amlodipine	Clinical Pharmacology and Therapy. 2014, 23 (1). – P.87-92.	A.S. Kolbin, A.A. Kurylev, M.A. Proskurin, Y.E. Balykina
5.	ASSESSMENT OF MEDICAL TECHNOLOGIES USED IN HIV INFECTION	HIV infection are immunosuppression. – 2014.- Issue 1 – P.110-116.	Kolbin A.S., Pavlysh A.V.

6.	Federal Guidelines for Physicians on the Use of Drugs (formulary system)"	Volume XV, Moscow, 2014	Edited by A.G. Chuchalin
7.	Pharmacoeconomic Analysis of Botulinum Toxin in Complex Therapy for Cerebral Palsy	Good Clinical Practice. – 2014. - Issue 1. – P. 14-24.	Kolbin A.S., Vilium I.A., Proskurin M.A., Balykina Y.E.
8.	Health Technology Assessment of Hyaluronans in Osteoarthritis Treatment	Good Clinical Practice. – 2014. - Issue 1. – P. 40-57.	Kolbin A.S., Vilium I.A., Balykina Y.E., Proskurin M.A.
9.	Assessment of the Economic Evaluation of the Contrast Agent MultiHance	Good Clinical Practice. – 2014. - Issue 1. –P. 57-68.	Kolbin A.S., Vilyum I.A.
10.	Assessment of the Economic Feasibility of the Contrast Agent Iomeron in Percutaneous Coronary Intervention	Good Clinical Practice. 2014. - Issue 1. – P. 68-77	Kolbin A.S., Vilyum I.A.
11.	Microeconomic Tools Application for Marketing: Health Care Expenses in the Modern Russia	Journal of Management and Marketing, Scientific Publisher. 2014;2 (1): 19—26.	Prasolov A.V., Kolbin A.S.
12.	ASSESSMENT OF MEDICAL TECHNOLOGIES USED IN HIV INFECTION	HIV infection are immunosuppression. – 2014.- Issue 1 – P.110-116.	Kolbin A.S., Pavlysh A.V.
13.	Role of Randomized Trials in Pharmacoepidemiology	Pharmacoeconomics. Modern Pharmacoepidemiology and pharmacoeconomics. – 2014. Vol. 7. Issue 1. – P. 1 – 7.	Galankin T.L., Kolbin A.S.
14.	Pharmacoeconomic Usefulness of the Drug Giotrif® (Afinib) in first-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer with a Mutation of Epidermal Growth Factor Receptor (EGRFR)	Modern Oncology. – 2014. – Vol. 16. – Iss. 2. – P. 66-73.	A.S. Kolbin, A.A. Kurylev, A.V. Pavlysh, M.A. Proskurin, Yu.E. Balykina
15.	Systematic Review of Mathematical Models Used for Predicting Bacterial Resistance	Clinical Microbiology and Antimicrobial Chemotherapy. 2014. – Vol.16. – Iss. 2. – P.137-143.	Arepyeva M.A., Kolbin A.S., Kurylyov A.A., Balykina Yu. E., Sidorenko S.V.
16.	Assessment of the economic feasibility of gadoversetamide (OptiMARK) in MRI with intravenous contrast	Good Clinical Practice. – 2014. - Issue 2. – P. 77-81.	Kolbin A.S., Vilum I.A.
17.	Pharmacoeconomic Analysis of using Dabigatran Etextilate (Pradaksa®) in Comparison with Other Anticoagulants for the	Clinical Pharmacology and Therapy. – 2014. - 23 (5). – P.91-96.	A.S. Kolbin, A.A. Kurylev, M.A. Proskurin, Y.E. Balykina

	Treatment of Pulmonary Embolism and Deep Venous Thrombosis		
18.	MODERN APPROACHES TO THE ORGANIZATION OF TRANSLATION RESEARCH	Pediatric Pharmacology. – 2014. – Vol. 11.-Iss. 3.- P.15-20	Kolbin A.S., Gapeshevin R.A., Malyshev S.M.
20.	Economic Analysis of Prolonged-Release Tacrolimus (Advagraf®) for the Prevention and Treatment of Liver Transplant Rejection in adult patients	Clinical Pharmacology and Therapy. – 2014. –Vol.23. Iss. 4. P. 103-108.	Kolbin A.S., Kurylev A.A., Proskurin M.A., Balykina Yu. E.
21.	Pharmacoeconomic Analysis of the Use of Ribomustin® in 1 <sup>st</sup> Line Therapy of Multiple Myeloma for Patients Older than 65 Years	Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology. 2014. – 7(2). – P.6– 12.	Kolbin A.S., Vilum I.A., Balykina Yu.E., Proskurin M.A.
22.	The Cost-Effectiveness Analysis of Use of Dydrogesterone in Premenstrual Syndrome	Value in health. 2014;17(7): PgA508. ISPOR 17 annual European Congress. November 8-12. 2014. PIH22.	Kolbin A., Vilum I., Balykina Yu., Proskurin M.
23.	Pharmacoeconomic Analysis of the Use of Sunitinib (Sutent) in First-Line Treatment of Metastatic Renal Cell Carcinoma.	Practical Pharmacoeconomics. Vol. 2. Broncho-pulmonology, Oncology, Gynecology, Neurology (research collection), 2014. - P.31-44.	Kolbin A.S., Kurilev A.A., Pavlysh A.V.
24.	Pharmacoeconomic Examination of the Use of Certain Progestogens in Treatment of Recurrent Pregnancy Loss	Gynecology, Obstetrics and Perinatology. 2014, - Vol. 13, Iss. 6, P. - 12–17	A.S.Kolbin, I.A.Vilyum, M.A.Proskurin, Yu.E.Balykina
25.	Pharmacoeconomic Expertise of Using Duphaston® in Obstetrics and Gynecology under Threatened Miscarriage.	Effective pharmacotherapy. Obstetrics and Gynecology. 2014. – Iss. №5. – P.18-24	Kolbin A.S., Vilyum I.A., Proskurin M.A., Balykina Y.E.
26.	Pharmacoeconomic Analysis of Oxaliplatin in Chemotherapy for Colorectal Cancer. Data from Actual Clinical Practice.	Pharmacoeconomics. 2014. – Vol.7.- Iss. 3.-P..26-29.	Pavlysh A.V., Kolbin A.S., Kasimova A.R.
27.	Pharmacoepidemiology of botulinum toxin in the complex therapy of poststroke spasticity in the Russian Federation. The survey data of neurologists	Good Clinical Practice. – 2014. – Iss. 3. – P. 18-23	Kolbin A.S., Vilum I.A.

28.	Pharmacoeconomic aspects of androgen blockade by goserelin for locally advanced prostate cancer in patients receiving radiation therapy	Problemy standartizatsii v zdravoochranenii. 2014. – 7- P. 8-14.	Rudakova A.V., Petrov S.B.
29.	Pharmacoeconomic aspects of vaccination of children by 13-valent pneumococcal conjugate vaccine in the Russian Federation	Voprosy sovremennoi pediatrii. 2014. – 13(1). - P.51-59.	Rudakova A.V., Baranov A.A., Lobzin Yu.B., Briko N.I., Namazova-Baranova L.S., Tatochenko V.K., Charit S.M., Sidorenko S.V., Korolyova I.S., Kozlov R.S., Mayanski N.A., Kostinov M.P., Snegova N.F.
30.	Pharmacoeconomic aspects of apixaban and other new oral anticoagulants use in patients with non-valvular atrial fibrillation	Kardiologia. 2014. – 54(7). - P. 43-52.	Rudakova A.V., Tatarski B.A.
31.	Cost-effectiveness of paricalcitol and combination of cinacalcet and nonselective preparations of vitamin D in chronic kidney disease at fifth stage in the Russian Federation	Nephrologia. 2014. – 18(6). - P. 64-70.	Niuiten M., Rudakova A.V., Marshall T.
32.	Clinical and pharmacoeconomic aspects of heart failure therapy by selective aldosterone antagonist eplerenone	Consilium Medicum. 2014. 16(5). - P. 47-50.	Rudakova A.V., Moiseeva O.M.
33.	Cost-effectiveness of abiraterone in patients with castration-resistant prostate cancer previously treated with docetaxel	Onkourologia. 2014. - 3. - P. 73-77.	Rudakova A.V., Meshkov D.O., Mishugin S.V
34.	Pharmacoeconomic aspects of prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: apixaban compared with warfarin and acetylsalicylic acid	Ratsionalnaya farmakoterapia v kardiologii. 2014. – 10(3). - P. 275-282.	Rudakova A.V., Parfenov V.A.
35.	Pharmacoeconomic aspects of diagnosis of tuberculosis in patients with HIV infection using GENE XPERT MTB/RIF method	VICH-infektsia i immunosupressia. 2014. – 6(4). - P.51-56.	Shumlyanskaia V.E., Rudakova A.V.

36.	Pharmacoeconomic aspects of HIV therapy using fixed antiretroviral drug combinations	VICH-infektsia i immunosupressia. 2014. – 6(1). - P. 97-100.	Rudakova A.V.
36.	Efficiency of conjugate pneumococcal vaccine to prevent pneumococcal disease	Zhurnal infektologii. 2014. 6(2). - P. 43-47.	Perova A.L., Rudakova A.V., Charit S.M.
37.	Assesment of prevented expenses for rotavirus infection treatment by vaccination with 5-valent vaccine in the Russian Federation	Zhurnal infektologii. 2014. 6. - 2. - P. 71-75.	Rudakova A.V., Charit S.M., Uskov A.N., Lobzin Yu.V.
38.	Cost analysis of the first line antiretroviral therapy in the Russian Federation	Zhurnal infektologii. 2014. 6. - 1. - P. 72-77	Rudakova A.V.
39.	Cost-effectiveness of different approaches to the diagnosis of tuberculosis in patients with HIV infection	Epidemiologia i infeksionnye bolezni. Aktualnye voprosy. 2014. - 5. - P. 21-28.	Shumlyanskaia V.E., Rudakova A.V.
40.	Pharmacoeconomic aspects of immunodeficiency virus therapy using fixed combination of highly active antiretroviral therapy (emtricitabine/ rilpivirine/ tenofovir)	Infeksionnye bolezni: novosti, mneniya, obuchenie. 2014. - 2 (7). - P.89-97.	Rudakova A.V., Meshkov D.O., Serebryakov E.M.
41.	Pharmacoeconomic aspects of use of intestinal gel containing levodopa and carbidopa in Parkinson's disease	Zhurnal nevrologii i psichiatrii. 2014.- 10. - P.80-84.	Rudakova A.V., Yakupov E.Z.
42.	Assessment of the economic efficiency of the anesthetic nefopam in therapy postoperative pain	Good Clinical Practice, 2014. - №3. – P.27 - 34.	Belousov D.U., Afanasyeva E.V., Efremova E.A.
43.	Analysis of the epidemiological indicators of type 2 diabetes in the adult population of Moscow	Diabetes mellitus. 2014. 3. - P. 5 – 16.	Kalashnikova M.F., Suntsov Y.I., Belousov D.U., Kantemirova M.A.
44.	Pharmacoeconomics of dapagliflozin in patients with type 2 diabetes mellitus with inadequate glycemic control.	Good Clinical Practice, №3, 2014. - P. 3 - 17.	Ziryanov S.K., Kalashnikova M.F., Belousov D.U., Afanasyeva E.V.

45.	Comparative evaluation of economic efficiency of modern inhaled anesthetics.	Good Clinical Practice, №2, 2014. – P. 3 - 20.	Belousov D.U., Afanasyeva E.V., Efremova E.A.
46.	Pharmacoeconomic analysis of adjuvant use of zonisamide therapy resistant partial epilepsy in adults.	Good Clinical Practice, №1, 2014, - P. 35 - 50.	Belousov D.U., Afanasyeva E.V., Efremova E.A.
47.	Pharmacoeconomic analysis of perampanel for resistance partial epilepsy.	Good Clinical Practice, №1, 2014, - P.24 - 39.	Belousov D.U., Afanasyeva E.V., Efremova E.A.
48.	Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects.	Good Clinical Practice, №1, 2014, - P.3 - 13.	Belousov D.U., Afanasyeva E.V.
49.	Pharmacoeconomic aspects of the diabetic ketoacidosis prevention in type 1 diabetes mellitus by self-monitoring of blood ketones.	Good Clinical Practice, №2, 2014, - P.58 - 65.	Petryaykina E.E., Belousov D.U., Rybkina I.I., Koltunov I.E.
50.	Provision of medicines care provided in municipal health care institutions in the Moscow region in stationary conditions (2012 – 2014 years).	Good Clinical Practice, №3, 2014, - P.30 - 35.	Malaev M.G.
51.	Analysis of drug purchases after the entry into force of the federal contract system	Good Clinical Practice, №1, 2014, - P.77 - 82.	Malaev M.G.
52.	Analysis of drugs procurement to ensure the provision of medical care in hospitals.	Good Clinical Practice, №1, 2014, - P.83 - 86.	Malaev M.G.

## II. Oral and Poster Presentations at the ISPOR International Meeting and European Congress:

1. The cost-effectiveness analysis for use of dydrogesterone in premenstrual syndrome. Kolbin A. , Vilum I., Balykina Yu. , Proskurin M. ISPOR 17 annual European Congress. November 8-12. 2014.
2. Cost-effectiveness of apixaban compared to warfarin and aspirin in patients with non-valvular atrial fibrillation in the Russian Federation. A.V. Rudakova, V.A. Parfenov. *Value in Health*. 2014. PCV97. ISPOR 17 annual European Congress. November 8-12. 2014.

## III. Oral and Poster Presentations at the Russian Meeting on health economics and health technology assessment researches:

1. Toporov S.E., Rudakova A.V., Sizova N.V., Zacharova N.G., Rassochin V.V. Pharmacoeconomic analysis of first-line HAART. Application of the "decision tree" model // Collection of materials of the II Russian scientific-practical conference with international participation "Innovation in Health of the Nation".- S.-Petersburg, November 17, 2014- P. 231-234.
2. Shumlyanskaia V.E., Rudakova A.V. Cost-benefit analysis of the different approaches to the diagnosis of tuberculosis in HIV-infected population // Collection of materials of the II Russian scientific-practical conference with international participation "Innovation in Health of the Nation".- S.-Petersburg, November 17, 2014- P. 254-257.

3. Shumlyanskaia V.E., Rudakova A.V. Cost-effectiveness of different algorithms of diagnosis of tuberculosis in patients with HIV infection // Proceedings of the III Congress of the National Association of Phthisiologists, 27.11.134-29.11.14. ".- S.-Petersburg: the National Association of Phthisiologists: 2014. -P.202
4. Samarina A.V., Rudakova A.V. Evaluating cost-effectiveness of prevention programs for perinatal transmission of HIV and family planning programs among HIV-infected women // Collection of materials of the IV Conference on HIV / AIDS in Eastern Europe and Central Asia. Moscow, 2014 - P.275.
5. Rovny V.B., Rudakova A.V., Babchenko I.V. Epidemiological and pharmaco-economic rationale for prevention of respiratory syncytial infection in children // Materials of the VIII Russian forum with international participation "Children's health: prevention and treatment of socially significant diseases". S.-Petersburg.- 2014.- P. 227.
6. Rudakova A.V., Lobzin Yu.B. Sidorenko S.V., Charit S.M. Assessment of the cost-effectiveness of vaccination of infants against pneumococcal disease with 10-valent pneumococcal vaccine // Mat. XVII Congress of Pediatricians of Russia with international participation "Actual problems of Pediatrics".- 2014.- P. 283.

**IV. Oral Presentations at the Russian Meeting on health economics and health technology assessment researches:**

№ пп.	Conference Title	Organizers	Paper Title	Date	Venue
1.	"Medicine and Pharmacology" Workshop of the Social Service Guardianship Council of the Russian Federation.	Russian Medical Society	Medicine and Pharmacology	27/12/2013	Moscow
2.	IX All-Russian Medical Forum	Russian Medical Society	Pharmacovigilance in the Russian Federation.  State of the art.  The role of a doctor.	23/1/2014	Moscow
3.	Training Seminar (5th Interregional Conference) of All-Russian project for the Training of Scientific Personnel in the field of Clinical Pharmacology, Pharmacoeconomics and Drug	Association of Clinical Pharmacologists of the Russian Federation	Health Technology Assessment: Application Prospects and Practical Experience.	4/2/2014	Moscow



	Supply				
4.	"Medicine and Pharmaceutics" Workshop	Social Service Guardianship Council of the Russian Federation.	Interchangeability of Drugs	4/2/2014	Moscow
5.	Discussion of the Issues of Health Technology Assessment Implementation in the Russian Federation	The Federal Antimonopoly Service Expert Council for Developing Competition in Social and Public Health Services	What Do We Use When Assessing Health Technologies?	10/2/2014	Москва
6.	II International Scientific and Practical Symposium "HIV-infection and pharmacoconomics"	North-West Department of RAMS,  Health Committee of St.-Petersburg	Health Technology Assessment in HIV Infection	14/2/2014	Saint Petersburg
7.	Roundtable "Selecting the Induction Treatment for Patients with Kidney Transplant"	MoH of Sverdlovsk region	Pharmaco-economic Aspects of Induction Therapy in Kidney Transplantation.	3/4/2014	Ekaterinburg
8.	All-Russian Meeting "Actual Problems of Clinical Pharmacology and Drug Supply" Interregional Scientific and Practical Conference "Actual Problems of Clinical Pharmacology and Drug Supply"	Ministry of Health of the Russian Federation	The Experience of Distance Learning in Clinical Pharmacology at the Postgraduate Stage of Training for Doctors	23/4/2014	Saratov

9.	All-Russian Meeting "Actual Problems of Clinical Pharmacology and Drug Supply" Interregional Scientific and Practical Conference "Actual Problems of Clinical Pharmacology and Drug Supply"	Ministry of Health of the Russian Federation	Pharmacoeconomic Ground of Innovative Therapy of Bronchial Asthma	24/4/2014	Saratov
10.	XVI International Congress on Antimicrobial Therapy	The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), European Society of Clinical Microbiology and Infectious Disease (ESCMID), Alliance for the Prudent Use of Antibiotic (APUA), The International Society of Chemotherapy (ISC),	Mathematical Models for Predicting Resistance by Analyzing the Consumption of Antibiotics	21/5/2014	Moscow
11.	Biologics and Biosimilars – Regulatory and Clinical Aspects. Modern Challenges to Regulatory System. Expert Session	National Research Institute of Public Health, Russian Academy of Sciences	Adverse Events of biologics	29/5/2014	Moscow
12.	Topical Issues of Preclinical and Clinical Trials of Drugs and	Ministry of Health of the Russian Federation	Comparative Effectiveness Research – a Modern Challenge in the Paradigm of	10/6/2014	Saint-Petersburg

	Medical Devices		Clinical Trials		
13.	SAINT-PETERSBURG SEPTIC FORUM	Health Committee of St.-Petersburg;  Territorial Compulsory Medical Insurance Fund of St. Petersburg;  Saint-Petersburg I.I. Dzhanelidze Research Institute of Emergency Care	Pharmacoeconomic Aspects of Empirical Therapy	11-13/9/2014	Saint-Petersburg
14.	PRACTICAL ASPECTS OF COMPILING DOSSIER FOR INCLUSION OF DRUGS IN VED  Workshop	The Society of Professional Pharmaceutical Organizations	The Structure of the Dossier; Pharmacology as a Basis for the Inclusion of the Drug; Quantitative and Qualitative Indicators – Priority	30/9/2014	Moscow
15.	The Introduction of Health Technology Assessment in the Russian Federation	Social Platform "UNITED RUSSIA"	The Role of Expertise in Circulation of Drugs and Medical Devices	1/10/2014	Moscow
16.	Meeting of Chief Experts (Oncology) "Improving the Results of Treatment in Patients with Metastatic Renal Cell Carcinoma"	Health Committee	Clinical and Economic Aspects of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma	15/10/2014	St.-Petersburg
17.	IX Scientific and Practical Congress with International Participation "Rational Pharmacotherapy	Health Committee of St.-Petersburg;  Professional Medical Association of	Special Aspects of Biologics Safety Monitoring	17/10/2014	St.-Petersburg

	2014"	Clinical Pharmacologists of St.-Petersburg			
18.	5th Scientific Conference "Rational Pharmacotherapy"	Health Committee of St.-Petersburg	Do We Know Everything About Drugs After Clinical Trials?	29/10/2014	St.-Petersburg
19.	IV Annual International Partnering Forum «Life Sciences Invest. Partnering Russia»	SPCPA, Government of St. Petersburg	Financing Health Care System. Compulsory Health Insurance. High-Tech Medical Care. Various Approaches and Models of Drug Supply System Development. Prototype Models.	18/11/2014	Saint Petersburg
20.	International Forum "Health Technology Assessment in Russia", IV Session.	WHO, RAMS	New Requirements for the Formation of Limited Lists: Are There Any Signs of HTA?	2/12/2014	Moscow
21.	International Conference on Computer Technologies in Physical and Engineering Applications (ICCTPEA)	St. Petersburg State University, IVESC International Steering Committee, St. Petersburg State Polytechnic University, Moscow Institute of Physics and Technology State University, Lebedev Physical Institute of the Russian Academy of Sciences (RAS), Kotel'nikov Institute of	Modern Approaches to Drug Research and Development Using Mathematical Modeling	June 30 – July 4, 2014	Saint-Petersburg

		Radio Engineering and Electronics of RAS, Scientific Council of RAS on Physical Electronics, American Vacuum Society, Interregional Innovative development Center "INNO-MIR", Russian Foundation for Basic Research.			
22.	Conjoint ISPOR Russia HTA and ISPOR St Petersburg Chapters Meeting, ISPOR 17 <sup>th</sup> Annual European Congress	ISPOR	Mathematic Modeling Methods as a Necessary Instrument of Assessing Medical Technologies. Is it Possible to Use this Instrument under the Current System of Compiling Limited Drug Lists in Russia?	11/11/2014	Amsterdam
23.	2nd International Educational Forum "Russian Days of the heart"	Russian Medical Society	Pharmacoeconomic aspects of prevention of thromboembolic complications in patients with atrial fibrillation	2/6/2014	St. Petersburg
24.	XIII International Workshop of continuing medical education (CME) in nephrology, under the auspices of the International Society of Nephrology (ISNGO) («Week Nephrology 2014")	Russian Medical Society	Pharmacoeconomic aspects of treatment of secondary hyperparathyroidism in hemodialysis patients	2/6/2014	St. Petersburg
25.	XVI Moscow International	RUSSIAN MEDICAL	Pharmacoeconomic aspects of the	16// 2014	Moscow,

	Course on endovascular diagnosis and treatment	SOCIETY	left atrial appendage occlusion in patients with atrial fibrillation		16-
26.	VIII Congress with international participation "Development of pharmacoconomics and Pharmacoepidemiology in the Russian Federation"	RUSSIAN MEDICAL SOCIETY	Pharmaco-economic aspects of treatment of lung cancer	4/4/2014	Rostov-on-Don,
27.	The Fifth Meeting of the Russian Society of Interventional Cardioangiologists	RUSSIAN MEDICAL SOCIETY	Evaluation of the cost-effectiveness of WATCHMAN device implantation for occlusion of the left atrial appendage in patients with atrial fibrillation compared with anticoagulant therapy	28/4/2014	Moscow
28.	IX Congress with international participation "Rational pharmacotherapy - 2014"	SPb	Cost-effectiveness of intestinal gel Levodopa / carbidopa in patients with severe Parkinson's disease", "Cost-effectiveness of targeted therapy for metastatic castration-resistant prostate cancer	16/10/2014	St. Petersburg
29.	2nd Interregional Scientific and Practical Symposium "HIV - medicine and pharmacoconomics"	RUSSIAN MEDICAL SOCIETY	Pharmaco-economic aspects of the treatment of HIV infection with the use of fixed combinations of antiretroviral drugs	14/2/2014	St. Petersburg
30.	VI Annual All-Russian Congress on Infectious Diseases	RUSSIAN MEDICAL SOCIETY	Pharmaco-economic aspects of vaccination against pneumococcal infections in the Russian Federation	25/3/2014	Moscow

31.	Public Coordinating Council for pneumococcal disease in Russia	RUSSIAN MEDICAL SOCIETY	Performance criteria used for pharmacoeconomic evaluation of vaccines	13/12/2014	Moscow
32.	Assembly of Experts of Northwestern Federal District "Interdisciplinary approach in the diagnosis and treatment of immune-mediated diseases"	RUSSIAN MEDICAL SOCIETY	Cost-effectiveness for biological drugs for the treatment of rheumatoid arthritis	6/6/2014	St. Petersburg
33.	Workshop of experts in Moscow "Interdisciplinary approach in the diagnosis and treatment of immune-mediated diseases"	RUSSIAN MEDICAL SOCIETY	Pharmacoeconomic aspects of choice of biological products for the treatment of rheumatoid arthritis	1/11/2014	Moscow

#### V. Meeting created by Chapter:

1. Actual problems of HTA and health care system financing in Russia. 11/11/2014ia: new challenges of the health care system. ISPOR 17 annual European Congress. November 8-12. Amsterdam.
2. Life Sciences Invest. *Partnering Russia*, Saint Petersburg, 18/11/2014.

#### VI. Own educational courses

1. Main issues of health technology assessment (technology used in health care. The schedule was 6 days a week during 1 month, totally 144 hours. May, 2014. Saint Petersburg.

Name of sections and disciplines: Stages of drug development; Health technology assessment (HTA): history, goals, and the basic principles; Models and approaches for HTA; Effectiveness and efficacy of health technologies; Comparative studies; Adverse events; Basics of clinical and economic analysis; Pharmacoeconomics; Analysis of the results; Working with literature; Medical statistics; Reporting and publishing of the results; Development, adoption and evaluation of management decisions; Using HTA to justify the selection of therapy - some legal issues.

#### VII. Translation of ISPOR Good Practices for Outcomes Research Articles (Available for Translation).

1. Retaining, and Enhancing, the QALY. Translator (name, title, organization, position): Irina Villum; MD, PhD; First State Medical University of St. Petersburg. Reviewer (name, title, organization, position): Sviatoslav Plavinski MD, PhD, DSc, North-West State Medical University named after I. I. Mechnikov, Dept. Head.
2. QALYs: Some Challenges. Translator (name, title, organization, position): Irina Villum; MD, PhD; First State Medical University of St. Petersburg. Reviewer (name, title, organization, position): Sviatoslav

- Plavinski MD, PhD, DSc, North-West State Medical University named after I. I. Mechnikov, Dept. Head.
3. QALYs: The Basics. Translator (name, title, organization, position): Irina Villum; MD, PhD; First State Medical University of St. Petersburg. Reviewer (name, title, organization, position): Sviatoslav Plavinski MD, PhD, DSc, North-West State Medical University named after I. I. Mechnikov, Dept. Head.
  4. The Use of QALYs in Clinical and Patient Decision-Making: Issues and Prospects. Translator (name, title, organization, position): Irina Villum; MD, PhD; First State Medical University of St. Petersburg. Reviewer (name, title, organization, position): Alexey Kolbin, MD, PhD, DSc, professor, First State Medical University of St. Petersburg.
  5. Toward a Consensus on the QALY. Translator (name, title, organization, position): Irina Villum; MD, PhD; First State Medical University of St. Petersburg. Reviewer (name, title, organization, position): Belousov Dmitry, CEO, Center of pharmacoconomics & outcomes research, Russia, Moscow
  6. Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Translator (name, title, organization, position): Alexey Kurilev; MD; First State Medical University of St. Petersburg. Reviewer (name, title, organization, position): Alexey Kolbin; MD, PhD, DSc; First State Medical University of St. Petersburg; professor, head of the Department of Clinical Pharmacology.
  7. Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report. Translator (name, title, organization, position): Alexey Kurilev; MD; First State Medical University of St. Petersburg. Reviewer (name, title, organization, position): Alexey Kolbin; MD, PhD, DSc; First State Medical University of St. Petersburg; professor, head of the Department of Clinical Pharmacology.
  8. Validation of Electronic Systems to Collect Patient-Reported Outcome (PRO) Data—Recommendations for Clinical Trial Teams: Report of the ISPOR ePRO Systems Validation Good Research Practices Task Force. Translator (name, title, organization, position): Andrey Pavlysh; MD, PhD; First State Medical University of St. Petersburg. Reviewer (name, title, organization, position): Alexey Kolbin; MD, PhD, DSc; First State Medical University of St. Petersburg; professor, head of the Department of Clinical Pharmacology and Elena Verbitskaya, Docent, PhD, First Pavlov State Medical University, associate professor.
  9. Recommendations on Evidence Needed to Support Measurement Equivalence between Electronic and Paper-Based Patient-Reported Outcome (PRO) Measures: ISPOR ePRO Good Research Practices Task Force Report. Translator (name, title, organization, position): Andrey Pavlysh; MD, PhD; First State Medical University of St. Petersburg. Reviewer (name, title, organization, position): Elena Verbitskaya, Docent, PhD, First Pavlov State Medical University, associate professor.
  10. Multinational Trials—Recommendations on the Translations Required, Approaches to Using the Same Language in Different Countries, and the Approaches to Support Pooling the Data: The ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force Report. Translator (name, title, organization, position): Andrey Pavlysh; MD, PhD; First State Medical University of St. Petersburg. Reviewer (name, title, organization, position): Elena Verbitskaya, Docent, PhD, First Pavlov State Medical University, associate professor.
  11. Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5. Translator (name, title, organization, position): Gapeschin Roman, MD, St Petersburg State University. Reviewer (name, title, organization, position): Sviatoslav Plavinski MD, PhD, DSc, North-West State Medical University.
  12. Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Translator (name, title, organization, position): Gapeschin Roman, MD, St Petersburg State University. Reviewer (name, title, organization, position): Sergey Zyryanov; MD, PhD, DSc, professor; Russian National Research Medical University.
  13. Pediatric Patient-Reported Outcome Instruments for Research to Support Medical Product Labeling: Report of the ISPOR Good Research Practices for the Assessment of Patient-Reported Outcomes in Children and Adolescents Task Force. Translator (name, title, organization, position): Gapeschin Roman, MD, St Petersburg State University. Reviewer (name, title, organization, position): Alexey Kolbin, MD, PhD, DSc, professor, First State Medical University of St. Petersburg.
  14. Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Translator (name, title, organization, position): Timofey Galankin, MD, First Pavlov State Medical University, associate professor. Reviewer (name, title,



organization, position): Alla Rudakova, PharmD, PhD, DSc, Professor, St. Petersburg State Chemical-Pharmaceutical Academy.

15. Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Translator (name, title, organization, position): Yulia Balykina; MS, PhD; St Petersburg State University. Reviewer (name, title, organization, position): Sergey Zyryanov; MD, PhD, DSc, professor; Russian National Research Medical University.

#### **VIII. Journals where we are editors and can provide ideology and methodology of pharmacoconomics and health technology assessment**

1. Good Clinical Practice. [www.clininvest.ru](http://www.clininvest.ru)

#### **IX. Own websites**

1. <http://www.labclinpharm.ru>
2. <http://www.healtheconomics.ru>